Skip to main content
. 2022 Jul 16;15:69–85. doi: 10.2147/TACG.S365613

Table 5.

Relation Between Low and High Expression of Circ0075001expression with Clinical Data in AML Patients (N = 66)

Circ0075001 Expression Test of Sig. p
Low Median (<3.01) (n=33) High Median (>3.01) (n=33)
No. % No. %
Sex
 Male 21 63.3 16 48.5 χ2=1.538 0.215
 Female 12 36.4 17 51.5
Age (years)
 Min. – Max. 24.0–75.0 19.0–75.0 t=1.236 0.221
 Mean ± SD. 48.73 ± 13.17 53.36 ± 17.06
 Median 49.0 58.0
Splenomegaly 5 15.2 21 63.6 χ2=16.246 <0.001*
Hepatomegaly 5 15.2 20 60.6 χ2=14.488 <0.001*
Lymphadenopathy 1 3.0 3 9.1 χ2=1.065 FEp=0.613
CNS involvement 0 0.0 2 6.1 χ2=2.063 FEp=0.492
B.M BLASTS
 Min. – Max. 20.0–90.0 20.0–90.0 U=522.50 0.775
 Mean ± SD. 44.88 ± 24.77 40.55 ± 22.11
 Median (IQR) 32.0 30.0
FAB
 M1 3 9.1 5 15.2 χ2=22.144 MCp=0.001*
 M2 12 36.4 1 3.0
 M3 8 24.2 3 9.1
 M4 6 18.2 5 15.2
 M5 2 6.1 9 27.3
 M6 1 3.0 4 12.1
 M7 1 3.0 6 18.2
Overall survival (months)
 Min. – Max. 1.0–12.0 1.0–12.0 U=273.0 <0.001*
 Mean ± SD. 10.0 ± 3.44 5.91 ± 4.17
 Median 12.0 4.0
Outcome
 Died 10 30.3 19 57.6 χ2=10.693 MCp=0.004*
 Alive 22 66.7 9 27.3
 Lost FU 1 3.0 5 15.2
Cytogenetic criteria
 Favorable 23 69.6 10 30.4 χ2=10.25 P=0.005*
 Intermediate 5 15.2 11 33.3
 Adverse 5 15.2 12 33.3
CR achievement 23 69.7 8 24.2 χ2=13.687 <0.001*
TLC x 103
 Min. – Max. 0.80–23.0 1.10–21.0 U=519.50 0.748
 Mean ± SD. 9.32 ± 6.93 8.51 ± 6.28
 Median 7.50 6.20
Hb gm/dl
 Min. – Max. 5.0–11.80 3.0–11.30 t=2.197 0.032*
 Mean ± SD. 8.84 ± 1.54 7.87 ± 2.02
 Median 9.0 7.50
PLT x 103
 Min. – Max. 17.0–150.0 10.0–100.0 U=472.0 0.352
 Mean ± SD. 58.97 ± 30.77 51.36 ± 27.74
 Median 55.0 50.0

Notes: p, p-value for comparing between different parameters *statistically significant at p ≤ 0.05.

Abbreviations: χ2, chi-square test; MC, Monte Carlo; FE, Fisher Exact t: Student’s t-test; U, Mann Whitney test.